Effects of phosphatidylserine therapy in geriatric patients with depressive disorders

Maggioni, Marco; Picotti, G. B.; Bondiolotti, G P; Panerai, A; Cenacchi, T.; Nobile, P.; Brambilla, Frăncesca

doi:10.1111/j.1600-0447.1990.tb06494.x

Cited by 58 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2B). This result is consistent with the report that an intraperitoneal administration of BC-PS (15 mg / kg for 30 days) increased the avoidance performance of lowresponding rats (18) and may be partly explained by the anti-depressive effect of PS (22).…”

Section: Discussionsupporting

confidence: 82%

Enhanced Learning of Normal Adult Rodents by Repeated Oral Administration of Soybean Transphosphatidylated Phosphatidylserine

Kataoka-Kato¹,

Ukai²,

Sakai³

et al. 2005

J Pharmacol Sci

View full text Add to dashboard Cite

Abstract. Soybean lecithin transphosphatidylated phosphatidylserine (SB-tPS) is already known to improve the learning ability of aged or drug-induced amnesic rodents. In this study, its effect on normal adult rodents was evaluated using several learning tasks. Firstly, three behavioral tests (open-field, Y-maze, and active avoidance test) were consecutively carried out after the daily oral administration of SB-tPS (50 mg / kg per day, for 34 days). Repeated oral administration of SB-tPS did not affect either exploratory behavior in the open-field test or spontaneous alternation behavior in the Y-maze test, while mice pretreated with SB-tPS showed significant enhancement of conditioned avoidance response. Secondly, the brightness discrimination test was used to evaluate the effect of SB-tPS on learning ability. The daily oral administration of SB-tPS (50 mg / kg per day, for 27 days) to normal rats significantly increased the correct response ratio in the brightness discrimination test. Finally, to elucidate the necessity of SB-tPS pretreatment, another active avoidance test was carried out, and no enhancement of conditioned avoidance response was observed in non-pretreated mice. These results suggest that repeated administration of SB-tPS could enhance the learning ability of normal adult rodents as those of aged ones.

show abstract

Section: Discussionsupporting

confidence: 82%

Enhanced Learning of Normal Adult Rodents by Repeated Oral Administration of Soybean Transphosphatidylated Phosphatidylserine

Kataoka-Kato¹,

Ukai²,

Sakai³

et al. 2005

J Pharmacol Sci

View full text Add to dashboard Cite

show abstract

“…Subjects in the PS+PA group did not have any significant mood changes from baseline (late summer/early fall) to the end of the study in (late fall/winter), however in the placebo group a seasonally expected mood deterioration was observed (P<0.001 in pre-post comparison). This is consistent with a different report that PS had a positive effect on geriatric depression [36].…”

Section: Study 1: Effect Of Ps+pa On Memory and Mood In Functioning Esupporting

confidence: 82%

Soy Lecithin-Derived Phosphatidylserine Plus Phosphatidic Acid: Effects on Brain Functions in Elderly Patients with Alzheimer's Disease and Dementia

Moré¹,

Rutenberg²

2017

J Aging Sci

View full text Add to dashboard Cite

Phosphatidic acid (PA) and phosphatidylserine (PS) and are natural constituents of healthy brain cell membranes, which have been recognized since the 1970s as essential to normal neuronal functioning. PA is a precursor in the formation of other phospholipids, including PS and phosphatidylethanolamine (PE). Also, it has an impact on membrane rigidity/flexibility, which is important in modulating exo-and endocytosis. PS is also an important precursor for PE synthesis. Since PS predominantly occurs in brain cells, but normal diets do not include the consumption of brains, PS is available to our brains mostly via natural "production" in our bodies.Here, we present a tabulated literature survey of clinical studies on PS and/or PA regarding brain function in elderly people. In addition we give a summary on two of our our already published pilot studies performed with a brain-health food supplement containing a proprietary blend of 100 mg PS and 80 mg PA produced from soy lecithin: A three-month double-blind, placebo-controlled study demonstrated the positive influence of three PS+PA capsules/ day, (300 mg PS+240 mg PA per day; n=40)) or placebo (n=32) on memory and mood in functioning, non-depressive elderly people with memory problems. In a two-month randomized, double-blind, placebo-controlled study, three PS+PA capsules/day (300 mg PS+240 mg PA per day; n=56) or placebo (n=40) improved daily functioning, mental health, emotional state, and self-reported general condition in patients with Alzheimer's disease (AD).Altogether there is encouraging clinical data that PS+PA supplementation could be beneficial to AD patients and other elderly people with memory or cognition problems. Long-term studies are, however, still lacking. Keywords: Phosphatidylserine (PS) and Phosphatidic Acid (PA) in MemoryThe membrane phospholipids phosphatidic acid (PA) and phosphatidylserine (PS) are essential to cellular functioning, acting as a biological detergent, keeping fatty substances soluble and cell membranes flexible [1,2]. During the pathogenesis of several age-related neurodegenerative diseases, including Alzheimer's disease, the neuronal membrane lipid composition is altered in the brain [3,4]. Also, the lipid raft composition appears to be altered in neurodegenerative diseases [5]. PS (and PA), produced by enzymatic conversion of soybean lecithin, avoids possible regulatory and safety issues regarding bovine spongiform encephalopathy. Soy lecithin-derived PS is absorbed and metabolized, with elevated serum levels for at least 1.5 hours after an oral dose, as has been shown within a kinetic study on 8 human volunteers. The baseline serum level of PS in relation to the level of total serum phospholipids was around 2%. 30 minutes after ingestion, it started to increase, peaking at 90 minutes after intake at around 4%, and returning to the basal level 180 minutes after intake [23].Recently, oral administration of phosphatidylcholine/phosphatidylethanolamine (PE) -transphosphatidylated PS has been shown to improve memory imp...

show abstract

“…Mood improvements have been previously reported in a double-blind trial of PS in depressed patients [87]. A number of studies have also demonstrated that phospholipids may have anti-stress effects, as demonstrated by lowered levels of adrenocorticotropic hormone (ACTH), reduction in perceived stress ratings in response to acute stress [88] and reduced cortisol release in response to acute stress [89,90].…”

Section: Introductionmentioning

confidence: 99%

A randomized controlled trial investigating the neurocognitive effects of Lacprodan® PL-20, a phospholipid-rich milk protein concentrate, in elderly participants with age-associated memory impairment: the Phospholipid Intervention for Cognitive Ageing Reversal (PLICAR): study protocol for a randomized controlled trial

Scholey

Camfield

Hughes

et al. 2013

Trials

View full text Add to dashboard Cite

BackgroundAge-related cognitive decline (ARCD) is of major societal concern in an ageing population, with the development of dietary supplements providing a promising avenue for amelioration of associated deficits. Despite initial interest in the use of phospholipids (PLs) for ARCD, in recent years there has been a hiatus in such research. Because of safety concerns regarding PLs derived from bovine cortex, and the equivocal efficacy of soybean-derived PLs, there is an important need for the development of new PL alternatives. Phospholipids derived from milk proteins represent one potential candidate treatment.MethodsIn order to reduce the effects of age-associated memory impairment (AAMI) the Phospholipid Intervention for Cognitive Ageing Reversal (PLICAR) was developed to test the efficacy of a milk protein concentrate rich in natural, non-synthetic milk phospholipids (Lacprodan® PL-20). PLICAR is a randomized, double-blind, placebo-controlled parallel-groups study where 150 (N = 50/group) AAMI participants aged > 55 years will be randomized to receive a daily supplement of Lacprodan® PL-20 or one of two placebos (phospholipid-free milk protein concentrate or inert rice starch) over a 6-month (180-day) period. Participants will undergo testing at baseline, 90 days and 180 days. The primary outcome is a composite memory score from the Rey Auditory Verbal Learning Test. Secondary outcomes include cognitive (verbal learning, working memory, prospective and retrospective memory, processing speed and attention), mood (depression, anxiety, stress and visual analogue scales), cardiovascular (blood pressure, blood velocity and pulse wave pressure), gastrointestinal microbiota and biochemical measures (oxidative stress, inflammation, B vitamins and Homocysteine, glucoregulation and serum choline). Allelic differences in the Apolipoprotein E and (APOE) and Methylenetetrahydrofolate reductase (MTHFR) gene will be included for subgroup analysis. A subset (N = 60; 20/group)) will undergo neuroimaging using functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG) in order to further explore in vivo central mechanisms of action of Lacprodan® PL-20. This study will enable evaluation of the efficacy of milk-derived phospholipids for AAMI, and their mechanisms of action.Trial RegistrationThe trial is jointly funded by Arla Foods and Swinburne University of Technology, currently recruiting and is registered on the Australian New Zealand Clinical Trials Registry as ACTRN12613000347763.

show abstract

Effects of phosphatidylserine therapy in geriatric patients with depressive disorders

Cited by 58 publications

References 18 publications

Enhanced Learning of Normal Adult Rodents by Repeated Oral Administration of Soybean Transphosphatidylated Phosphatidylserine

Enhanced Learning of Normal Adult Rodents by Repeated Oral Administration of Soybean Transphosphatidylated Phosphatidylserine

Soy Lecithin-Derived Phosphatidylserine Plus Phosphatidic Acid: Effects on Brain Functions in Elderly Patients with Alzheimer's Disease and Dementia

Contact Info

Product

Resources

About